U.K. May Retain Value-Based Pricing, Even If Health Care Bill Fails
This article was originally published in The Pink Sheet Daily
The U.K.’s Health and Social Care Bill is struggling in parliament, but even if it falls, the government’s plans for value-based drug pricing may survive.
You may also be interested in...
Value-Based Pricing Could Boost Global Applicability Of NICE Appraisals
Value-based pricing will start in the U.K. in January 2014 for newly launched products, with prices taking into account innovation and societal benefit as well as NICE's usual clinical and cost-effectiveness analysis, U.K. Health Secretary Andrew Lansley tells NICE's annual conference.
European Regulatory Round-Up: EMA And The UK Heed The Calls Of Industry; France Is Otherwise Occupied
The European Medicines Agency follows through on its transparency initiative with comprehensive list of products under review and also reduces pharmacovigilence data reporting requirements.
EU Transparency Directive Revisions May Accelerate Access To New Medicines, But IP Issues Set To Cause A Storm
Proposed revisions to the EU Transparency Directive could drive faster access to medicines. But innovative product sponsors say IP rules will damage their business.